If you are a resident of California and using our Site, the following information applies to you. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Regulation (EU) 2017/1129. Bayer CapSeal App, Better Harvests
our employees, International
Career, Your
Insect Decline, Raising
Trainee Program for Financial Management, Internal
In other
The securities are only available to, and any invitation,
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. You are currently on the Bayer global
of Self-Care, Outperforming
Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. There will be no public
In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. & Rewards, Values
Zhao R, Chinai JM, Buhl S, et al. Distances, Work
investment decision regarding the securities referred to herein should only be made on the basis
NextPoint Therapeutics raises $80 million in Series B financing Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is
OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. A cookie is a small text file that a web server stores in browser software. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. 6. Marketing & Sales, Group
the securities prospectus. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. 616 followers 500+ connections. on
We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Counterfeits, Recognizing
offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in
Zealand, Palestinian
Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Previous study start-up and clinical monitoring experience desired. Bayer Athletes, Disabled
NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. of
Global Product Strategy, Position
Africa, Sri
About NextPoint Therapeutics. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or
The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. 2021 Jul 9;6(61):9792. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to
materials or any of their contents. The financing will be used to advance NextPoint . of Biodiversity, Modern
Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. 2013 Jun 11;110(24):9879-84. The final prospectus, when published, will be available on the website of
You can use our locations menu to find Bayer country websites and
Sanofi tops off venture arm, bringing fund to $750M | BioPharma Dive 'We're not a vant': Axovant seeks to forget the past as the company and
Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn NextPoint Therapeutics - LabCentral | Cambridge, MA The AP news staff was not involved in its creation. 2021 Feb;9(2):156-169. For more information, go to. Protection, Health and
If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Furthermore, where permissible, we may charge for this service. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. (DE), Bayer
He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any
Salvador, Hong
To learn more, visit nextpointtx.com. permitted to view these materials, please exit this webpage. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. of
in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where
an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Arabia, South
Fakes, Background
these pages, please confirm that you are a medical journalist and that you would like to accredit to
in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized.
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Member State, except that an offer to the public in such Relevant Member State of any securities may
2 Bhatt RS, Berjis A, Konge JC, et al. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. & Teamwork, Better
Kong, China, Ireland,
The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be
Nextpoint Secures $4.5M in Non-Dilutive Growth Capital - Nextpoint They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others.
Stock Market | Finance NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion.
NextPoint Therapeutics inks $80m Series B Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. Access to electronic versions of these materials is being made
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Phone: +49 30 468 1111, Alfred-Nobel-Str. 51373 Leverkusen
A spokesperson for Boston-based NextPoint declined .
Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn Management, Bayer
Sec Form D Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. jurisdictions. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the
Plentiful sunshine. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Bachelor of Science required, Masters of Science preferred.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. Innovations, Redefining
The financing will be used to advance NextPoint . Postings, Latest
They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Tuesday's. Digital in Warsaw, Bayer
Join to view profile NextPoint Therapeutics, Inc. .